Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

(2015) D. J. Buurman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

(2015) David Drobne et al.   Clinical Gastroenterology and Hepatology

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases

(2015) Thomas Van Stappen et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

(2015) Niels Vande Casteele et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease

(2015) X. Roblin et al.   Journal of Crohns & Colitis

Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease

(2015) Douglas L. Nguyen et al.   Therapeutic Advances in Chronic Disease

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

(2014) B. G. Levesque et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

(2014) Parambir S Dulai et al.   GUT

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease

(2013) Toshifumi Hibi et al.   JOURNAL OF GASTROENTEROLOGY

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

(2012) Martin Bortlik et al.   Journal of Crohns & Colitis

Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages

(2011) Raja Atreya et al.   GASTROENTEROLOGY

Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner

(2010) Anne Christine W. Vos et al.   GASTROENTEROLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY